Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 28;14(1):90.
doi: 10.1186/1532-429X-14-90.

Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials

Affiliations

Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials

Songtao Liu et al. J Cardiovasc Magn Reson. .

Abstract

Background: Cardiac magnetic resonance (CMR) T1 mapping has been used to characterize myocardial diffuse fibrosis. The aim of this study is to determine the reproducibility and sample size of CMR fibrosis measurements that would be applicable in clinical trials.

Methods: A modified Look-Locker with inversion recovery (MOLLI) sequence was used to determine myocardial T1 values pre-, and 12 and 25min post-administration of a gadolinium-based contrast agent at 3 Tesla. For 24 healthy subjects (8 men; 29 ± 6 years), two separate scans were obtained a) with a bolus of 0.15mmol/kg of gadopentate dimeglumine and b) 0.1mmol/kg of gadobenate dimeglumine, respectively, with averaged of 51 ± 34 days between two scans. Separately, 25 heart failure subjects (12 men; 63 ± 14 years), were evaluated after a bolus of 0.15mmol/kg of gadopentate dimeglumine. Myocardial partition coefficient (λ) was calculated according to (ΔR1myocardium/ΔR1blood), and ECV was derived from λ by adjusting (1-hematocrit).

Results: Mean ECV and λ were both significantly higher in HF subjects than healthy (ECV: 0.287 ± 0.034 vs. 0.267 ± 0.028, p=0.002; λ: 0.481 ± 0.052 vs. 442 ± 0.037, p < 0.001, respectively). The inter-study ECV and λ variation were about 2.8 times greater than the intra-study ECV and λ variation in healthy subjects (ECV:0.017 vs. 0.006, λ:0.025 vs. 0.009, respectively). The estimated sample size to detect ECV change of 0.038 or λ change of 0.063 (corresponding to ~3% increase of histological myocardial fibrosis) with a power of 80% and an alpha error of 0.05 for heart failure subjects using a two group design was 27 in each group, respectively.

Conclusion: ECV and λ quantification have a low variability across scans, and could be a viable tool for evaluating clinical trial outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sample size required in each group to detect a certain ECV difference with a two group design of 80% power and an alpha error of 0.05. The X axis values corresponding to the ECV difference need to be detected like the first column in Table 4. The three curves corresponding to case 1, 2 and 3 of Table 4. The smaller ECV difference and higher inter-study SD, the larger the sample size needed. The dashed line corresponding to the sample size needed to detect a 0.038 ECV difference for the three cases as showed in Table 4.
Figure 2
Figure 2
Sample size required in each group to detect a certain partition coefficient difference with a two group design of 80% power and an alpha error of 0.05. The X axis values corresponding to the partition coefficient difference need to be detected like the first column in Table 4. The three curves corresponding to case 1, 2 and 3 of Table 4. The smaller partition coefficient difference and higher inter-study SD, the larger the sample size needed. The dashed line corresponding to the sample size needed to detect a 0.063 partition coefficient difference for the three cases as showed in Table 4.

References

    1. Marijianowski MM, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol. 1995;25:1263–1272. doi: 10.1016/0735-1097(94)00557-7. - DOI - PubMed
    1. Gazoti Debessa CR, Mesiano Maifrino LB, de Mesiano Maifrino LB. Age related changes of the collagen network of the human heart. Mech Ageing Dev. 2001;122:1049–1058. doi: 10.1016/S0047-6374(01)00238-X. - DOI - PubMed
    1. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903. doi: 10.1016/j.jacc.2010.11.013. - DOI - PMC - PubMed
    1. Brooks A, Schinde V, Bateman AC, Gallagher PJ. Interstitial fibrosis in the dilated non-ischaemic myocardium. Heart. 2003;89:1255–1256. doi: 10.1136/heart.89.10.1255. - DOI - PMC - PubMed
    1. Udelson JE. Heart failure with preserved ejection fraction. Circulation. 2011;124:e540–e543. doi: 10.1161/CIRCULATIONAHA.111.071696. - DOI - PubMed

Publication types

MeSH terms